Molecular portraits of intratumoral heterogeneity in human ovarian cancer

Cancer Letters

Volumn 307, Issue 1, 2011, Pages 62-71

  Choi, Yoon Pyo ^a   Shim, Hyo Sup ^a   Gao, Ming Qing ^a   Kang, Suki ^a   Cho, Nam Hoon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Array CGH; Cancer stem like cell; Human ovary cancer; Intratumoral heterogeneity; Side population

Indexed keywords

BELOTECAN; BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; CD24 ANTIGEN; CHEMOKINE; CISPLATIN; CYCLIN DEPENDENT KINASE 4; CYTOKINE; DOCETAXEL; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; HISTONE DEACETYLASE 1; INTEGRIN; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 12; NOTCH RECEPTOR; PACLITAXEL; PER1 PROTEIN; PER2 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR A; PROTEIN KINASE B; PROTEIN S 100; STEM CELL FACTOR RECEPTOR; TOPOTECAN; TRANSCRIPTION FACTOR FKHRL1; WNT PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CANCER STEM CELL; CELL HETEROGENEITY; CELL PROLIFERATION; CHEMOSENSITIVITY; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MOLECULAR CLONING; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE POPULATION CELL; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CHROMOSOME ABERRATIONS; CLONE CELLS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPHENOTYPING; MIDDLE AGED; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIDE-POPULATION CELLS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 79957480642     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.018     Document Type: Article

References (43)

1. Scully R.E. Recent progress in ovarian cancer. Hum. Pathol. 1970, 1:73-98.
2. Wang V., Li C., Lin M., Welch W., Bell D., Wong Y.F., Berkowitz R., Mok S.C., Bandera C.A. Ovarian cancer is a heterogeneous disease. Cancer Genet. Cytogenet. 2005, 161:170-173.
3. Nguyen H.G., Ravid K. Tetraploidy/aneuploidy and stem cells in cancer promotion: the role of chromosome passenger proteins. J. Cell Physiol. 2006, 208:12-22.
4. Bapat S.A. Evolution of cancer stem cells. Semin. Cancer Biol. 2007, 17:204-213.
5. Zucchi I., Astigiano S., Bertalot G., Sanzone S., Cocola C., Pelucchi P., Bertoli G., Stehling M., Barbieri O., Albertini A., Schöler H.R., Neel B.G., Reinbold R.A., Dulbecco R. Distinct populations of tumor-initiating cells derived from a tumor generated by rat mammary cancer stem cells. Proc. Natl. Acad. Sci. USA 2008, 105:16940-16945.
6. Al-Hajj M., Clarke M.F. Self-renewal and solid tumor stem cells. Oncogene 2004, 23:7274-7282.
7. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
8. Berry N.B., Bapat S.A. Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype. J. Ovarian Res. 2008, 24:1-8.
9. Szotek P.P., Pieretti-Vanmarcke R., Masiakos P.T., Dinulescu D.M., Connolly D., Foster R., Dombkowski D., Preffer F., Maclaughlin D.T., Donahoe P.K. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc. Natl. Acad. Sci. USA 2006, 103:11154-11159.
10. Tu S.M., Lin S.H., Logothetis C.J. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol. 2002, 3:508-513.
11. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2005, 444:756-760.
12. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
13. Hirschmann-Jax C., Foster A.E., Wulf G.G., Nuchtern J.G., Jax T.W., Gobel U., Goodell M.A., Brenner M.K. A distinct " side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 2004, 101:14228-14233.
14. Challen G.A., Little M.H. A side order of stem cells: the SP phenotype. Stem Cells 2006, 24:3-12.
15. Triel C., Vestergaard M.E., Bolund L., Jensen T.G., Jensen U.B. Side population cells in human and mouse epidermis lack stem cell characteristics. Exp. Cell Res. 2004, 295:79-90.
16. Gao M.Q., Choi Y.P., Kang S., Youn J.H., Cho N.H. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010, 29:2672-2680.
17. Wei X., Dombkowski D., Meirelles K., Pieretti-Vanmarcke R., Szotek P.P., Chang H.L., Preffer F.I., Mueller P.R., Teixeira J., MacLaughlin D.T., Donahoe P.K. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc. Natl. Acad. Sci. USA 2010, 107:18874-18879.
18. Kang S., Shim H.S., Lee J.S., Kim D.S., Kim H.Y., Hong S.H., Kim P.S., Yoon J.H., Cho N.H. Molecular proteomics imaging of tumor interfaces by mass spectrometry. J. Proteome Res. 2010, 9:1157-1164.
19. Gao M.Q., Kim B.G., Kang S., Choi Y.P., Park H., Kang K.S., Cho N.H. Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J. Cell Sci. 2010, 123:3507-3514.
20. Kim B.G., An H.J., Kang S., Choi Y.P., Gao M.Q., Park H., Cho N.H. Laminin-332-rich tumor microenvironment for tumor invasion in the interface zone of breast cancer. Am. J. Pathol. 2011, 178:373-381.
21. Kang S.M., Park M.S., Chang J., Kim S.K., Kim H., Shin D.H., Chung K.Y., Kim D.J., Sohn J.H., Choi S.H., Kim J., Yoon E.J., Kim J.H. A feasibility study of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) as a chemosensitivity test for lung cancer. Cancer Res. Treat. 2005, 37:223-227.
22. Goodell M.A., McKinney-Freeman S., Camargo F.D. Isolation and characterization of side population cells. Methods Mol. Biol. 2005, 290:343-352.
23. Song J., Shih IeM., Salani R., Chan D.W., Zhang Z. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. Clin. Cancer Res. 2007, 13:6842-6849.
24. Zhang S., Balch C., Chan M.W., Lai H.C., Matei D., Schilder J.M., Yan P.S., Huang T.H., Nephew K.P. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008, 68:4311-4320.
25. Burleson K.M., Casey R.C., Skubitz K.M., Pambuccian S.E., Oegema T.R., Skubitz A.P. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol. Oncol. 2004, 93:170-181.
26. Bapat S.A., Mali A.M., Koppikar C.B., Kurrey N.K. Stem and progenitor cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005, 65:3025-3029.
27. Ferrandina G., Bonanno G., Pierelli L., Perillo A., Procoli A., Mariotti A., Corallo M., Martinelli E., Rutella S., Paglia A., Zannoni G., Mancuso S., Scambia G. Expression of CD133-1 and CD133-2 in ovarian cancer. Int. J. Gynecol. Cancer 2008, 18:506-514.
28. Baba T., Convery P.A., Matsumura N., Whitaker R.S., Kondoh E., Perry T., Huang Z., Bentley R.C., Mori S., Fujii S. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009, 28:209-218.
29. Kristiansen G., Denkert C., Schlüns K., Dahl E., Pilarsky C., Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am. J. Pathol. 2002, 161:1215-1221.
30. Choi Y.L., Kim S.H., Shin Y.K., Hong Y.C., Lee S.J., Kang S.Y., Ahn G. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecol. Oncol. 2005, 97:379-386.
31. Kristiansen G., Pilarsky C., Pervan J., Stürzebecher B., Stephan C., Jung K., Loening S., Rosenthal A., Dietel M. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004, 58:183-192.
32. Kristiansen G., Schlüns K., Yongwei Y., Denkert C., Dietel M., Petersen I. CD24 is an independent prognostic marker of survival in non-small cell lung cancer patients. Br. J. Cancer 2003, 88:231-235.
33. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
34. Kristiansen G., Sammar M., Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J. Mol. Histol. 2004, 35:255-262.
35. Lim S.C. CD24 and human carcinoma: tumor biological aspects. Biomed. Pharmacother. 2005, 59(Suppl 2):S351-354.
36. Iwabuchi H., Sakamoto M., Sakunaga H., Ma Y.Y., Carcangiu M.L., Pinkel D., Yang-Feng T.L., Gray J.W. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res. 1995, 55:6172-6180.
37. Suzuki S., Moore D.H., Ginzinger D.G., Godfrey T.E., Barclay J., Powell B., Pinkel D., Zaloudek C., Lu K., Mills G. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res. 2000, 60:5382-5385.
38. Kiechle M., Jacobsen A., Schwarz-Boeger U., Hedderich J., Pfisterer J., Arnold N. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer 2001, 91:534-540.
39. Hu J., Khanna V., Jones M.W., Surti U. Comparative study of primary and recurrent ovarian serous carcinomas: comparative genomic hybridization analysis with a potential application for prognosis. Gynecol. Oncol. 2003, 89:369-375.
40. Makhija S., Sit A., Edwards R., Aufman K., Weiss H., Kanbour-Shakir A., Gooding W., D'Angelo G., Ferrell R., Raja S. Identification of genetic alterations related to chemoresistance in epithelial ovarian cancer. Gynecol. Oncol. 2003, 90:3-9.
41. Fishman A., Shalom-Paz E., Fejgin M., Gaber E., Altaras M., Amiel A. Comparing the genetic changes detected in the primary and secondary tumor sites of ovarian cancer using comparative genomic hybridization. Int. J. Gynecol. Cancer 2005, 15:261-266.
42. Helou K., Padilla-Nash H., Wangsa D., Karlsson E., Osterberg L., Karlsson P., Ried T., Knutsen T. Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors. Cancer Genet.Cytogenet. 2006, 170:1-8.
43. Bruchim I., Israeli O., Mahmud S.M., Aviram-Goldring A., Rienstein S., Friedman E., Ben-Baruch G., Gotlieb W.H. Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma. Cancer Genet. Cytogenet. 2009, 190:66-70.